EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strain diversity drives heterogeneous responses to tuberculosis combination therapy

Michelle H Yoon iD, Peter H Culviner, Mariana Pereira Moraes, Hidetomi Nitta, Nguyen Thuy Thuong Thuong, Sarah M Fortune iD, Bree B Aldridge iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01849-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Michelle H Yoon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Gates Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Strain diversity in Mycobacterium tuberculosis (Mtb) underlies distinct clinical presentations and outcomes, but the range of drug susceptibility phenotypes among clinical isolates is poorly understood. We aimed to identify drug response patterns in phylogenetically diverse clinical isolates to combination treatment. We selected 13 strains out of 641 drug-sensitive clinical isolates that capture local and global phylogenetic diversity and included Erdman ATCC-35801 as a reference. We treated each strain with 10 single drugs, 45 drug pairs, and 20 three-way combinations in standard and cholesterol-rich media. Mtb clinical strains displayed a broad range of drug response phenotypes across the 65 drug combinations and 2 metabolic conditions tested, with the most effective drug pairs (based on potency and synergy) varying by strain and metabolic condition. Within our 14-strain panel, strains that were less sensitive to single drugs were also less sensitive to combination treatment, with very few exceptions. For all drug combinations tested, the variation in combination potency was driven primarily by variation among genetically related strains, rather than between strains belonging to disparate lineages. Preclinical regimen design should reflect the diversity of Mtb clinical strains; our data suggest that selecting strains based on the range of drug response phenotypes displayed, rather than by genetic diversity alone, may better account for pathogen diversity. Our findings also show that constituent drug pairs of high-order combinations can be differentially effective against Mtb adapted to different carbon sources. Selection of these pairs should likely involve multiple factors including the infecting strain, metabolic niche, and drug response metrics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsTuberculosisMicrobial Sensitivity TestsHumansDrug Therapy, CombinationDrug SynergismPhylogenyPhenotypeGenetic VariationTreatment Effect Heterogeneity

Stichwörter der Autor:innen

Mycobacterium tuberculosisclinical isolatesdrug combinations

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University, Boston, Massachusetts, USA.
  • Department of Biomedical Engineering, Tufts University School of Engineering, Medford, Massachusetts, USA.

ORCID-Profile: Michelle H Yoon, Sarah M Fortune, Bree B Aldridge

Förderung

  • Wellcome Trust
  • Gates Foundation
  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health
  • Bill and Melinda Gates Foundation

Zitieren

APA

Yoon, M. H., Culviner, P. H., Pereira Moraes, M., Nitta, H., Thuong, N. T. T., Fortune, S. M., & Aldridge, B. B. (2026). Strain diversity drives heterogeneous responses to tuberculosis combination therapy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01849-25

Vancouver

Yoon MH, Culviner PH, Pereira Moraes M, Nitta H, Thuong NTT, Fortune SM, et al. Strain diversity drives heterogeneous responses to tuberculosis combination therapy. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01849-25

BibTeX
@article{Yoon2026,
  author = {Yoon, Michelle H and Culviner, Peter H and Pereira Moraes, Mariana and Nitta, Hidetomi and Thuong, Nguyen Thuy Thuong and Fortune, Sarah M and Aldridge, Bree B},
  title = {Strain diversity drives heterogeneous responses to tuberculosis combination therapy},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01849-25}
}
Kostenlos starten →